
CardiologyTalk
@cardiologytalk
Our goal is to bridge the educational gap confronting medical cardiologist and researchers with video interviews of principal investigators.
ID: 1320089567647526912
http://www.cardiologytalk.com 24-10-2020 19:48:11
335 Tweet
721 Followers
2,2K Following

Podcast - Moving from “Candidacy” To “Benefit Derived” Drs. Lala and Mentz Anu Lala-Trindade Mount Sinai Robert Mentz, MD #JCF #wordsmatter Link to Audio: hubs.la/Q01b4lpF0


Moving from “Candidacy” To “Benefit Derived” Drs. Lala and Mentz Anu Lala-Trindade Mount Sinai Robert Mentz, MD #JCF #wordsmatter hubs.la/Q01b40_l0


Podcast - Phase 2 PACIFIC-AF Study Jonathan P. Piccini, MD Jonathan Piccini, MD, MHS Duke Heart Duke Cardiology #PACIFICAF Link to Audio: hubs.la/Q01b4lnd0


Phase 2 PACIFIC-AF Study Jonathan P. Piccini, MD Jonathan Piccini, MD, MHS Duke Heart Duke Cardiology #PACIFICAF hubs.la/Q01b4rV00


Podcast - Phase III ORION-9,10, and 11 Studies Scott Wright, MD Professor Scott Wright Mayo Clinic #ORIONStudies Link to Audio: hubs.la/Q01b48nH0


Phase III ORION-9,10, and 11 Studies Scott Wright, MD Professor Scott Wright Mayo Clinic #ORIONStudies hubs.la/Q01b4g9p0


Podcast - Epi Scar-Homogenization With VS Without Epicardial Ablation Andrea Natale, MD Andrea Natale MD Texas Cardiac Arrhythmia Institute #VT #ICM Link to Audio: hubs.la/Q01b4x9g0


Epi Scar-Homogenization With VS Without Epicardial Ablation Andrea Natale, MD Andrea Natale MD Texas Cardiac Arrhythmia Institute #VT #ICM hubs.la/Q01b4vFV0


Non-RBC Blood Does Not Reduce Survival Following Surgery Ibrahim Sultan, MD Ibrahim Sultan UPMC Heart and Vascular Institute UPMC UPMC Physician Resources #CardioTwitter hubs.la/Q01bDSZ90


Podcast - Non-RBC Blood Does Not Reduce Survival Following Surgery Ibrahim Sultan, MD Ibrahim Sultan UPMC Heart and Vascular Institute UPMC UPMC Physician Resources #CardioTwitter Link to Audio: hubs.la/Q01bDV0H0


Phase 3 REDUCE-IT Trial Prakriti Gaba, MD Prakriti Gaba Dr. Deepak L. Bhatt Brigham and Women's Hospital @HarvardMed #REDUCEIT #CardioTwitter hubs.la/Q01bDZc30


EV ICD Pivotal Study: Will This Eliminate Complications? @drpaulfriedman Mayo Clinic Mayo Clinic CV #CardioTwitter medicusnetworks.net/3S4SRwB


EV ICD Pivotal Study: Will This Eliminate Complications? @drpaulfriedman Mayo Clinic Mayo Clinic CV #CardioTwitter medicusnetworks.net/3CzlsEy


Atrial Fibrillation SOC: An Electrophysiologist Review [2022] DJ Lakkireddy @bariatricsurgkc #Electrophysiology #CardioTwitter medicusnetworks.net/3MNb6Fv
![CardiologyTalk (@cardiologytalk) on Twitter photo Atrial Fibrillation SOC: An Electrophysiologist Review [2022] <a href="/DJ_Lakkireddy/">DJ Lakkireddy</a> @bariatricsurgkc #Electrophysiology #CardioTwitter
medicusnetworks.net/3MNb6Fv Atrial Fibrillation SOC: An Electrophysiologist Review [2022] <a href="/DJ_Lakkireddy/">DJ Lakkireddy</a> @bariatricsurgkc #Electrophysiology #CardioTwitter
medicusnetworks.net/3MNb6Fv](https://pbs.twimg.com/media/Ffhuj7yXkAIQ-6i.jpg)

@PrestonMasonPhD 🩺- How EPA can modulate platelet activation and thrombosis proteins in vascular endothelial cells during inflammation. Brigham and Women's Hospital #DeepakBhattMD #SamuelSherrattMD #PeterLibbyMD #ACC23 #WCCardio Watch and Share the Video Here: cardiologytalk.com/v/791


Icosapent Ethyl from 🥼 Professor Philippe Steg's discussion on the REDUCE-IT trial. Exciting to explore the remarkable benefits for patients with recent ACS. Assistance Publique – Hôpitaux de Paris (AP-HP) #PhilippeStegMD #ACC23 #WCCardio Watch and Share the Video Here: cardiologytalk.com/v/793


Dr. Mason The study highlights the impact of mineral oil, corn oil, EPA, and DHA on phospholipid membrane oxidation rates. Brigham and Women's Hospital #Amarincorp #DeepakBhattMD #SamuelSherrattMD #PeterLibbyMD #ACC23 #WCCardio


📢 Obacetrapib & Edizumab combo ROSE2 positive trial results in reduction of LDL cholesterol. Watch Michael Davidson Michael Davidson MD NewAmsterdam Pharma Corporation discuss the results buff.ly/3L7O24V


🔬 Marc S. Sabatine, MD, from Brigham and Women's Hospital, pioneers MK0616, a Merck PCSK9 inhibitor. LDL cholesterol drops by 60.9% in hypercholesterolemia patients—a potential healthcare game-changer! [video]buff.ly/3sRbM6Z #CardioResearch #LDLCholesterol #Innovation 🌟
![CardiologyTalk (@cardiologytalk) on Twitter photo 🔬 Marc S. Sabatine, MD, from <a href="/BrighamWomens/">Brigham and Women's Hospital</a>, pioneers MK0616, a Merck PCSK9 inhibitor. LDL cholesterol drops by 60.9% in hypercholesterolemia patients—a potential healthcare game-changer!
[video]buff.ly/3sRbM6Z
#CardioResearch #LDLCholesterol #Innovation 🌟 🔬 Marc S. Sabatine, MD, from <a href="/BrighamWomens/">Brigham and Women's Hospital</a>, pioneers MK0616, a Merck PCSK9 inhibitor. LDL cholesterol drops by 60.9% in hypercholesterolemia patients—a potential healthcare game-changer!
[video]buff.ly/3sRbM6Z
#CardioResearch #LDLCholesterol #Innovation 🌟](https://pbs.twimg.com/media/F6E6KmQXQAELz71.jpg)

Michael H. Davidson, MD, Michael Davidson MD NewAmsterdam Pharma Corporation shares groundbreaking results from the ROSE2 Trial on Obacetrapib! Discover a remarkable LDL cholesterol reduction with Obacetrapib + Ezetimibe, paving the way for aggressive LDL-C goals. 🎯👏 [video] buff.ly/3L7O24V
![CardiologyTalk (@cardiologytalk) on Twitter photo Michael H. Davidson, MD, <a href="/mdavidsonmd/">Michael Davidson MD</a> <a href="/NewAmsPharma/">NewAmsterdam Pharma Corporation</a> shares groundbreaking results from the ROSE2 Trial on Obacetrapib!
Discover a remarkable LDL cholesterol reduction with Obacetrapib + Ezetimibe, paving the way for aggressive LDL-C goals. 🎯👏
[video] buff.ly/3L7O24V Michael H. Davidson, MD, <a href="/mdavidsonmd/">Michael Davidson MD</a> <a href="/NewAmsPharma/">NewAmsterdam Pharma Corporation</a> shares groundbreaking results from the ROSE2 Trial on Obacetrapib!
Discover a remarkable LDL cholesterol reduction with Obacetrapib + Ezetimibe, paving the way for aggressive LDL-C goals. 🎯👏
[video] buff.ly/3L7O24V](https://pbs.twimg.com/media/F6FVobvWEAAVSHM.jpg)